The risk of SARS-CoV-2 outbreaks in low prevalence settings following the

removal of travel restrictions

AUTHORS

R. Sachak-Patwa[1], H.M. Byrne[1], L. Dyson[2,3], R.N. Thompson[2,3,*]

*Correspondence to: robin.n.thompson@warwick.ac.uk

AFFILIATIONS

[1]Mathematical Institute, University of Oxford, Oxford, UK

[2]Mathematics Institute, University of Warwick, Coventry, UK

[3]Zeeman Institute for Systems Biology and Infectious Disease Epidemiology Research,

University of Warwick, Coventry, UK

ABSTRACT

Countries around the world have introduced travel restrictions to reduce SARS-CoV-2

transmission. As vaccines are gradually rolled out, attention has turned to when travel

restrictions and other non-pharmaceutical interventions (NPIs) can be relaxed. Here,

using SARS-CoV-2 as a case study, we develop a mathematical branching process

model to assess the risk that, following the removal of NPIs, cases introduced into new

locations initiate a local outbreak. Our model accounts for changes in background

population immunity due to vaccination. We consider two locations in which the vaccine

rollout has progressed quickly – specifically, the Isle of Man (a British crown

dependency in the Irish Sea) and the country of Israel. Rather than aiming to make

exact quantitative predictions about the outbreak risk in different locations, we instead

use data from these locations to demonstrate the general principle that the outbreak risk

is unlikely to be eliminated completely when travel restrictions and other NPIs are

removed in low prevalence settings. This conclusion holds even once vaccine

programmes are completed. Key factors underlying these results are the potential for

transmission even following vaccination, incomplete vaccine uptake, and the recent

emergence of SARS-CoV-2 variants with increased transmissibility. Combined, these

factors suggest that when travel restrictions are relaxed, it will still be necessary to

implement surveillance of incoming passengers to identify infected individuals quickly.

This measure, as well as tracing and testing (and/or isolating) contacts of detected

infected passengers, should remain in place to suppress potential outbreaks until case

numbers globally are reduced.

KEYWORDS

mathematical   modelling;   infectious   disease   epidemiology;   outbreaks;   non-

pharmaceutical interventions; travel restrictions

1. INTRODUCTION

Combinations of non-pharmaceutical interventions (NPIs) have been introduced

worldwide to counter the COVID-19 pandemic [1–3]. These measures include travel

restrictions [4,5] and a range of other NPIs intended to reduce the numbers of contacts

between individuals [6]. The development and deployment of vaccines has also lowered

transmission [7–10] and reduced the number of individuals experiencing clinical

symptoms or severe disease once infected [11–13].

Effective NPIs have led to low levels of transmission in some locations. Australia and

New Zealand have often been cited as examples of countries that have implemented

NPIs effectively, with travel restrictions and quarantine of inbound travellers combined

with short-term lockdowns and contact tracing to identify infected contacts whenever

cases have been discovered [14–16]. Rigorous interventions targeted at inbound

travellers in low prevalence settings reflect the fact that imported cases can contribute

significantly to local incidence [17], and potentially initiate outbreaks with substantial

local transmission [18,19]. At the time of writing (1st May 2021), Israel is the country that

has vaccinated the largest proportion of its citizens, and the vaccination campaign there

has been credited with reducing transmission [8], prompting some NPIs to be removed.

Despite the success of both NPIs and vaccines, the current overall picture is

complicated. Vaccines do not prevent transmission entirely [7,20,21], and vaccine

uptake is incomplete, particularly in some ethnic groups and in underserved

communities [22]. Current tentative estimates suggest that first doses of the Pfizer and

AstraZeneca SARS-CoV-2 vaccines are around 60% effective at preventing infection,

with second doses leading to 65-85% effectiveness against infection [20]. Furthermore,

the appearance of novel SARS-CoV-2 variants makes eliminating transmission more

challenging. For example, the Alpha variant (B.1.1.7, or VOC 202012/01) that first

appeared in the United Kingdom in late 2020 has been found to be more transmissible

than the SARS-CoV-2 virus that originally emerged in China [23]. Although public

health measures have had some successes, these concerns raise a key question: Can

NPIs such as travel restrictions be removed without any risk in low prevalence settings

where vaccines have been distributed widely, or might outbreaks occur initiated by

SARS-CoV-2 reimportations from elsewhere?

Epidemiological models are often used to assess the risk of outbreaks in scenarios in

which the potential for pathogen transmission is not changing. According to the

mathematical theory of branching processes, the probability that cases introduced into a

new host population generate an outbreak driven by sustained local transmission is

given by

$$\text{Prob(outbreak)} = 1 - \left(\frac{1}{R}\right)^{I_0}, \qquad (1)$$

in which R is the reproduction number of the pathogen and I_0 is the number of

introduced infectious cases. This expression had been used to assess the risks of

outbreaks of pathogens including the Ebola virus [24–26], before being applied early in

the COVID-19 pandemic to assess outbreak risks outside China [19]. Equation (1)

reflects the risk that introduced cases generate an outbreak, and is based on a simple

transmission model in which individuals are assumed to mix homogeneously and

infected individuals are infectious for exponentially distributed time periods. Equation (1)

also involves an assumption that pathogen transmissibility is fixed at its current level. In

other words, the value of R is implicitly assumed to remain constant over the initial

phase of the potential outbreak. With a background of rapidly changing population

immunity due to vaccination acting to reduce transmission, this assumption may not be

accurate. To assess the risk of outbreaks if NPIs are removed during an ongoing

vaccination campaign using branching process models, standard epidemiological

modelling theory must be extended to account for temporally changing population

immunity.

Here, we use branching processes to investigate whether an introduced case is likely to

initiate an outbreak, accounting fully for temporal changes in population immunity due to

an ongoing vaccination campaign. We use four metrics to assess the risk of an outbreak

and consider two examples of vaccination campaigns from around the world, from the

Isle of Man and the country of Israel. In both locations, vaccination is progressing

quickly and prevalence is currently low. Given the relatively low numbers of cases in

these locations during the pandemic, there is also likely to be a background of limited

immunity from previous infections. We assess the risk of outbreaks in these places

when travel restrictions and other NPIs are removed, considering scenarios in which

NPIs are removed at different stages of the vaccination campaigns. Our goal is not to

develop a detailed epidemiological model for estimating precise outbreak risk estimates.

Instead, we use a simple model to show that, even when all vaccines have been

deployed in low prevalence settings (i.e. a maximum vaccination proportion v of

individuals have been vaccinated, where the precise value of v varies between

locations), the combination of incomplete vaccine uptake, imperfect vaccination and

variants of concern means that the risk of outbreaks due to imported cases will not be

eliminated completely when NPIs are removed. This highlights the need for careful

monitoring of imported cases until global prevalence is reduced to low levels. Until

vaccines are rolled out worldwide, there is still a risk of local transmission arising in low

prevalence settings initiated by importations from elsewhere.

2. METHODS

<u>Epidemiological model</u>

We performed our main analyses using a stochastic branching process model that

describes virus transmission in the initial stages of a potential outbreak. In this model,

following the arrival of a case in the local population, new infections occur at rate $\beta(1 -$

$\Lambda(t))$ and infected individuals have a mean infectious period of $1/\mu$ days (Fig 1a). The

times between successive events in the model are assumed to follow exponential

distributions. The function $\Lambda(t)$ reflects the extent to which transmission has been

reduced by vaccination, where a value of $\Lambda(t) = 0$ corresponds to an entirely

unvaccinated population. We consider scenarios in which travel restrictions and other

NPIs are removed, and transmission is only limited by vaccine-acquired immunity.

To model an ongoing vaccination campaign, we set $\Lambda(t) = \eta_1 V_1(t - \alpha) + \eta_2 V_2(t - \alpha)$,

where $V_1(t)$ is the proportion of individuals in the population who have received a single

vaccine dose at time t and $V_2(t)$ is the proportion of individuals in the population who

have received two vaccine doses at time t (Fig 1b). The parameters η_1 and η_2 reflect

the effectiveness of the vaccine at preventing infection after one and two effective

doses, respectively (specifically, η_1 and η_2 represent the multiplicative reduction in

susceptibility following one or two effective doses, compared to an unvaccinated

individual, so that $0 \leq \eta_1 \leq \eta_2 \leq 1$), and the parameter α represents the delay between

a vaccine dose being administered and being effective in the recipient. In our main

analyses, since we are modelling relatively low prevalence settings, we do not consider

immunity due to prior infections, although we present a supplementary analysis in which

we demonstrate the robustness of our results to this assumption.

Under this model, the time-dependent reproduction number, accounting for any

vaccines that have been administered and are effective at time t, is given by

149
$$R_V(t) = \frac{\beta(1 - \Lambda(t))}{\mu}. \qquad (2)$$

The value of $R_V(t)$ represents the expected number of secondary infections generated

by a single infected individual in the population at time t, under the assumption that no

further vaccinations take place in future. It is therefore representative of the

"instantaneous" transmissibility at time t. Indeed, $R_V(t)$ is sometimes referred to as the

instantaneous reproduction number [27–29]. In the absence of vaccination, so that $\Lambda(t) =$

0, then $R_V(t)$ is equal to the basic reproduction number, R_0.

(a)   Transmission model

(b)   Vaccination

Figure 1. The epidemiological model used in our analysis. (a) Following the introduction of an infected

individual into the host population, local transmission may happen with infections occurring at rate $\beta(1 -$

$\Lambda(t))$, where $\Lambda(t)$ reflects the vaccination coverage in the local population. The mean infectious period of

infected individuals is $1/\mu$ days. (b) The vaccination process is modelled by setting $\Lambda(t)$ according to the

proportion of individuals in the population who have been vaccinated with one (V_1) or two (V_2) doses. The

first vaccine dose is assumed to have effectiveness η_1 and the second vaccine dose has effectiveness η_2,

where the values of η_1 and η_2 are the multiplicative reductions in the susceptibility of individuals who have

been vaccinated with one or two vaccine doses, respectively (compared to an unvaccinated host).

Vaccine doses are effective α days after they are administered. This leads to declining population

susceptibility as a vaccine is rolled out across the population.

<u>Vaccination data</u>

In the model, $V_1(t)$ and $V_2(t)$ were set based on vaccination data from the location

under consideration (either the Isle of Man or Israel). Data describing the proportion of

the total population who had received one or two vaccine doses were available for the

periods up until 11th April 2021 (for the Isle of Man [30]) and 21st April 2021 (for Israel

[31]).

To explore how the risk of outbreaks is likely to change in future, we projected the

vaccine rollout forwards beyond these dates in the following way. We considered the

total population size of the location under consideration (denoted N), as well as the

numbers of individuals ($N_1(t)$ and $N_2(t)$) vaccinated with one or two doses, so that

$V_1(t) = N_1(t)/N$ and $V_2(t) = N_2(t)/N$. We assumed that a constant number of vaccine

doses are available each day in future (denoted D), and that there is a target period of τ

days between each vaccine dose. On any day in future, each available dose is assigned

to an individual who has been vaccinated with their first dose at least τ days ago, with

remaining doses then assigned to unvaccinated individuals. Resulting values of $N_1(t)$

and $N_2(t)$ were then converted to corresponding values of $V_1(t)$ and $V_2(t)$. To reflect the

fact that vaccine uptake is imperfect, and some population groups are not vaccinated,

we assumed that a maximum proportion ν of the population can ever be vaccinated.

Consequently, once the vaccination programme is completed, then $\Lambda(t) = \eta_2 \nu$. The

value of ν varies between locations, and depends on factors such as the age

distribution of the host population. Since there is uncertainty in the vaccine uptake going

forwards, we conducted supplementary analyses in which we considered a range of

different values of v. Values of the model parameters used in the analyses in the main

text for the Isle of Man and Israel are shown in Table 1.

Outbreak risk metrics

We used four different metrics to assess the risk that an infected individual, introduced

into the population at time t, initiates an outbreak driven by sustained local

transmission. The values of each of these metrics vary temporally. Each metric is used

to estimate the risk that an imported case initiates an outbreak under the assumption

that all travel restrictions and other NPIs are removed (in other words, pathogen

transmissibility at time t is determined by $R_V(t)$, which represents an adjustment to the

basic reproduction number R_0 due to vaccine-acquired immunity, as described above).

An overview of the four metrics explored is provided here; additional details are

available in the Supplementary Information.

The first metric we considered is the *Instantaneous Outbreak Risk (IOR)*. This quantity

represents the expression shown in equation (1), with $R = R_V(t)$ and $I_0 = 1$. The IOR

reflects the risk of an outbreak occurring starting from a single infected individual at time

t, but under the assumption that the vaccine rollout does not continue after time t so

that pathogen transmissibility is unchanged. While the IOR straightforward to calculate,

it does not reflect changing population immunity due to vaccination over the initial phase

of the potential outbreak. This standard metric is often used to assess the risk of

outbreaks in scenarios where pathogen transmissibility does not vary temporally

[19,24–26,32–34].

The second metric is the *Case Outbreak Risk (COR)*. The COR is an extension of the

IOR, accounting for changes in population susceptibility due to vaccination over the

initial phase of the potential outbreak. The COR has previously been used to assess

outbreak risks using branching processes for models in which pathogen transmission

varies periodically [32,35–37]. Its calculation involves solving the differential equation

225
$$\frac{dq(t)}{dt} = \beta(1 - \Lambda(t))q(t)\big(1 - q(t)\big) + \mu(q(t) - 1). \qquad (3)$$

The COR at time t is then given by $1 - q(t)$, where $q(t)$ represents the probability of an

outbreak failing to occur (i.e. ultimate extinction of the virus in the branching process

model [38]) starting from a single infected individual introduced into the population at

time t. Further details, including the derivation of equation (3), are provided in the

Supplementary Information.

The third metric we considered is the *Simulated Outbreak Risk (SOR)*. The SOR

involves repeated simulation of the branching process model, using the direct version of

the Gillespie stochastic simulation algorithm [39] adapted to account for temporally

varying pathogen transmissibility (due to changing population immunity). Simulations

were run starting with a single infected individual introduced into the population at time

t. The SOR then corresponds to the proportion of simulations in which a local outbreak

occurs; an outbreak is said to occur if the total number of individuals infected

simultaneously exceeds a pre-defined threshold value, M. In our analyses, we set $M =$

100.

Finally, we consider the *Numerical Outbreak Risk (NOR)*. The NOR is analogous to the

SOR, but with the advantage that it does not require large numbers of model

simulations to be run. The NOR, therefore, also represents the risk that a single infected

individual introduced into the population at time t initiates an outbreak in which at least

$M = 100$ individuals are ever infected simultaneously.

Table 1: Default parameter values used in our analyses.

Parameter	Description	Value	Source
β	Transmission rate	Set so that $R_0 = \frac{\beta}{\mu}$ takes a prescribed value	Two scenarios were considered, with mean R_0 values of 3 (similar to the original SARS-CoV-2 variant [40]) and 5 (similar to the Alpha variant (B.1.1.7) [23])
$1/\mu$	Duration of infectiousness	5 days	[41]
α	Delay between a vaccine dose being administered and being effective	14 days	[42]
η_1	Multiplicative reduction in susceptibility of an individual vaccinated with a single effective dose (compared to an unvaccinated host)	0.6	[20]
η_2	Multiplicative reduction in susceptibility of an individual vaccinated with two effective doses (compared to an unvaccinated host)	0.85	[20]
ν	Vaccine uptake	0.8 (Isle of Man) and 0.7 (Israel). Other values are	[43]

		considered in the Supplementary Information	
N	Total population size	84,500 (Isle of Man) and 8,772,800 (Israel)	[44]
D	Number of vaccine doses available each day (in future projections)	1,000 (Isle of Man) and 56,000 (Israel)	Average number of doses administered each day in the previous 30 days (up to 11 April 2021 for Isle of Man [30] and 21 April 2021 for Israel [31])
τ	Target period between vaccine doses (in future projections)	84 days (Isle of Man) and 21 days (Israel)	[45,46]

251   **3. RESULTS**

As described in the Methods, we first generated projections of the number of vaccinated

individuals in future for the Isle of Man (Fig 2a) and Israel (Fig 2d), based on past

vaccination data in those locations. To explore the impact of vaccination on virus

transmission, we calculated the time-dependent reproduction number ($R_V(t)$; equation

(2)) throughout the vaccination campaigns. We considered two different scenarios. In

the first, we set the mean value of R_0 (i.e. the reproduction number in the absence of

vaccination) equal to 3, as was the situation early in the COVID-19 pandemic (Fig 2b,e).

In the second scenario, we set the mean value of R_0 equal to 5 (Fig 2c,f) to reflect the

fact that currently circulating SARS-CoV-2 variants are more transmissible than the

original virus [23]. This second scenario is therefore likely to be a more realistic

reflection of the current and future risk.

Figure 2. Effect of vaccination on population susceptibility. (a) The proportion of the population of the Isle of Man that is unvaccinated $(1 - V_1(t) - V_2(t))$, vaccinated with a single dose $(V_1(t))$ and vaccinated with two doses $(V_2(t))$. The period in which vaccination data were available is shown in white, and the period in which vaccination data were projected is shown in purple. (b) The time-dependent reproduction number $(R_V(t))$ corresponding to the vaccination data in panel a, starting from a mean initial value of $R_V(0) = R_0 = 3$. To account for uncertainty in the value of R_0, a normal distribution was assumed about the mean value of R_0 with variance $\sigma^2 = 0.25$, which is reflective of the range of R_0 values estimated early in the COVID-19 pandemic [40]. (c) Analogous to panel b but starting from a mean initial value of $R_V(0) = R_0 = 5$. (d)-(f) Analogous to panels a-c but using vaccination data for Israel. In all panels, $t = 0$ days corresponds to 18th December 2020. Ticks on the x-axes refer to the starts of the months labelled. Parameter values are shown in Table 1.

We then calculated the values of the four different outbreak risk metrics throughout the period considered (18th December 2020 to 20th August 2021) based on these vaccination projections (Fig 3). This involves a scenario in which NPIs are removed

entirely, so that $R_V(t)$ is not reduced by interventions other than vaccination. These

metrics then reflect the risk that a single case first entering into the population at the

date of introduction shown initiates an outbreak driven by sustained local transmission,

given that no NPIs are in place. For each metric, and each time during the vaccination

programme, we calculated the outbreak risk by integrating over the full distribution for

$R_V(t)$ shown in Fig 2. In practice, the precise value of $R_V(t)$ is not known exactly at any

time: the purpose of this integration (which is over values of $R_V(t)$, rather than values of

t) is to account for this uncertainty in outbreak risk estimates. The resulting outbreak

risk therefore represents a point estimate of the risk accounting for uncertainty in

pathogen transmissibility.

The IOR represents the probability of sustained local transmission based only on the

value of $R_V(t)$ at the precise instance that the virus is introduced into the population.

When an introduction occurs while a vaccine is being deployed, there is a background

of decreasing population susceptibility, and so $R_V(t)$ may in fact decrease over the

initial stages of a potential outbreak. For that reason, it is unsurprising that the IOR

sometimes overestimates the outbreak risk compared to the other risk metrics (see e.g.

black lines in Fig 3a,c – and see Discussion).

In contrast, we found close agreement between the COR, SOR and NOR. Due to the

high assumed vaccine uptake in the Isle of Man, the outbreak risk at the end of the

vaccination programme there was calculated to be lower than when the vaccine rollout

was completed in Israel (although we also considered supplementary analyses with

different assumed vaccine uptake values – Fig S1). In the first scenario that we

considered (mean $R_0 = 3$), which is representative of the transmissibility of the original

SARS-CoV-2 virus, the outbreak risk was projected to be low following the vaccination

programme in the Isle of Man.

However, when the virus was assumed to be more transmissible (mean $R_0 = 5$), as is

the case for newly emerged variants of concern such as the Alpha variant (B.1.1.7), the

outbreak risk was found to be substantial even following the projected end of the

vaccination campaigns in both the Isle of Man and Israel. For example, when the

assumed vaccine uptake values of $v = 0.8$ and $v = 0.7$ had been achieved in the Isle of

Man and Israel, respectively, the NOR took values of 0.37 (95% Equal-Tailed Credible

Interval (CrI): [0.22,0.48], calculating using the 95% Equal-Tailed CrI for $R_V(t)$ at the

end of the vaccination rollout) and 0.51 (95% Equal-Tailed CrI: [0.39,0.59]) in those

locations. Given the uncertainty in epidemiological modelling projections, the key point

to note is that these values are greater than zero (rather than the exact outbreak risk

estimates themselves), suggesting that outbreaks can still occur when NPIs are

removed following the completion of vaccination programmes. This result is robust to a

range of assumptions surrounding virus transmission and the effectiveness of vaccines

(see Supplementary Information).

Figure 3. The risk that an infectious case introduced at each stage of the vaccination campaign initiates

an outbreak, if travel restrictions and other NPIs are removed. (a) The outbreak risk assessed using the

four metrics (IOR – black; COR – blue dashed; SOR – green dots; NOR – red), based on vaccination

data from the Isle of Man and assuming mean $R_0 = 3$, as in Fig 2b. The period in which vaccination data

were available is shown in white, and the period in which vaccination data were projected is shown in

purple. (b) Analogous to panel a but with mean $R_0 = 5$ (see Fig 2c). (c) Analogous to panel a but using

vaccination data for Israel (see Fig 2e). (d). Analogous to panel a but using vaccination data for Israel

with mean $R_0 = 5$ (see Fig 2f). Ticks on the x-axes refer to the starts of the months labelled. Parameter

values are shown in Table 1.

4. DISCUSSION

As vaccines are administered in countries around the world, attention has turned to the

possibility that transmission will soon be reduced to the extent that travel restrictions

and other NPIs can be relaxed. Here, we have investigated the impact of removing NPIs

on the risk of outbreaks occurring in locations with low prevalence and a significant

proportion of the population vaccinated. We used four metrics to estimate the risk that a

case introduced at any stage in the vaccination rollout leads to an outbreak driven by

local transmission, in a scenario in which NPIs are removed. We calculated temporal

changes in the values of these metrics in the context of vaccination in the Isle of Man

and in Israel, two locations with low prevalence and vaccination campaigns that have

progressed quickly.

We found that vaccination is leading to a substantial drop in the potential for virus

transmission in both the Isle of Man and Israel, as indicated by a decreasing value of

the time-dependent reproduction number, $R_V(t)$ (Fig 2). However, even when the

vaccine rollout is completed (with 80% of individuals fully vaccinated in the Isle of Man,

and 70% in Israel; other values are considered in the Supplementary Information), the

combination of vaccines not preventing transmission entirely, incomplete vaccine

uptake and the emergence of novel SARS-CoV-2 variants suggests that the risk of

outbreaks initiated by infected individuals arriving from elsewhere will not be eliminated

when NPIs are removed (Fig 3). This conclusion holds unless the vaccine uptake is very

high (Fig S1). This suggests that, when NPIs such as travel restrictions are relaxed, it

will still be advisable to be aware of the potential for local transmission. Ensuring that

case numbers are reduced elsewhere (i.e. in locations that imported cases might travel

from) will reduce the risk of importations, and strategies should be considered to

suppress outbreaks quickly if importations occur.

One potential use of our modelling framework by policy-makers is to identify the dates

on which travel restrictions can be relaxed, based on a maximum acceptable outbreak

risk. As an example, if the maximum acceptable value of the NOR is 0.4, then our

analysis with $R_0 = 5$ suggests that travel restrictions can be lifted on the Isle of Man at

the end of July 2021 (Fig 3b; the first date on which the NOR is projected to fall below

0.4 in our illustrative analysis is 29th July 2021). However, as described above, since the

risk of local transmission following introductions remains, it will be necessary to continue

to monitor inbound passengers in low prevalence settings to identify infected

individuals, even once vaccination programmes are completed.

Our modelling approach for assessing outbreak risks was motivated by studies in which

the potential for pathogen transmission varies periodically [32,35–37,47–50], due, for

example, to seasonal changes in weather conditions that affect transmission. In that

context, Carmona and Gandon [35] describe a "winter is coming effect", in which the

risk of an outbreak is lower than current environmental conditions suggest if conditions

become less favourable for transmission in the near future. In the terminology used in

our manuscript, if current environmental conditions promote pathogen transmission,

then the IOR is expected to be high. This is because the IOR reflects the outbreak risk

based on the conditions at the precise instance when the virus is introduced into the

population. However, if environmental conditions are expected to become less

favourable for transmission in the near future, then the values of the other risk metrics

are lower than the IOR, since those metrics account for changes in transmissibility over

the initial phase of the potential outbreak. Although in general we found a close

agreement between the four metrics that we considered, a background of decreasing

population susceptibility can lead to a similar effect in which the IOR is larger than the

COR, SOR or NOR (e.g. Fig 3a,c).

In this study, we used a simple branching process model to investigate the risk of

outbreaks when NPIs are removed during a vaccination programme. This involved

considering whether introduced cases are likely to lead to sustained local transmission

or instead fade out without causing an outbreak. We made the standard branching

process modelling assumption that population immunity is unaffected by infections in

the earliest stages of potential outbreaks [19,24–26,51,52]. In other words, infection-

acquired immunity following the arrival of the pathogen in the host population is not

considered. While this is reasonable when case numbers are low in the initial stages of

potential outbreaks, a more detailed model is needed to explore other quantities, such

as the eventual size of outbreaks. Following a vaccination programme, outbreaks are

likely to be smaller than those that occur before vaccines are widely administered.

Another simplification of our model is that we only accounted for changes in population

susceptibility due to the vaccine rollout. We did not account for prior immunity of some

members of the population due to previous exposures to the virus. At the time of writing

(1st May 2021), there have been 1,154 confirmed cases in the Isle of Man and 838,000

confirmed cases in Israel. Since these case numbers correspond to a relatively small

proportion of the host population (representing 1.4% and 9.6% of the population in the

Isle of Man and Israel, respectively), we do not expect this assumption to affect our key

findings. Furthermore, immunity is likely to wane over time [53–55], reducing the effect

of previous exposures on the outbreak risk. To test the potential impact of infection-

acquired immunity arising from cases occurring before May 2021, we also conducted a

supplementary analysis in which the value of R_0 is reduced by 1.4% in the Isle of Man

and 9.6% in Israel, and we found qualitatively similar results (Fig S2): even in this "best

case" scenario, there is still a risk of outbreaks due to imported cases once the

vaccination programmes are completed. Importantly, in other countries in which higher

numbers of cases have occurred, prior immunity may play a larger role in reducing the

risk of outbreaks compared to the low prevalence settings considered here.

Understanding the extent of this effect, based on the rate at which immunity wanes, is

an important target for further study.

In this research, we assumed that vaccines reduce transmission by lowering the

probability that a vaccinated host becomes infected compared to an unvaccinated host.

Two effective vaccine doses were assumed to reduce the probability of infection

substantially (by $\eta_2 = 0.85$), which is in line with estimates for the Pfizer vaccine used in

the UK Government's COVID-19 roadmap modelling [20]. However, there is uncertainty

about the precise level of protection offered by different COVID-19 vaccines. For that

reason, we also conducted a supplementary analysis (Fig S3) in which we considered a

range of values of η_2. In every scenario that we explored, the risk of outbreaks following

the completion of vaccination programmes in low prevalence settings was greater than

zero, with larger outbreak risks for lower values of η_2.

In addition to reducing the risk that a host becomes infected as assumed here [56],

vaccination may also reduce the risk of onwards transmission following infection [7],

reduce the risk of severe disease developing, or a combination of these effects [57]. In

principle, it would be possible to develop a more complex model that accounts for all of

these effects separately, at the cost of having to estimate (or assume) values of the

associated parameter values. It would also be possible to develop a transmission model

in which either vaccine- and/or infection-acquired immunity wanes. There is currently

significant uncertainty about the extent and speed of waning immunity, with hope that

antibody responses and/or cellular immune responses may provide long-lasting immune

memory, at least in some individuals [58,59]. Booster vaccination for vulnerable

individuals is currently being considered in several high-income countries, given the

possibility that vaccine-acquired immunity may wane. We note that any waning of

immunity will act to enhance our main qualitative conclusion that the risk of outbreaks is

unlikely to be eliminated completely in low prevalence settings by vaccination

programmes.

Other factors that may merit consideration in further analyses of future outbreak risks

include the impact of population-structure on both vaccine effectiveness [60] and

transmission [61,62], and the possibility that individuals' behaviours may be different

following the pandemic compared to beforehand, even when NPIs and travel restrictions

are removed. For precise quantitative outbreak risk predictions to be made, it may be

necessary to estimate R_0 in different locations. It would also be necessary to incorporate

changes in R_0 due to further new variants in our analyses, although we note that any

increase in transmissibility will act to strengthen our main conclusion that vaccine-

acquired immunity alone is unlikely to be sufficient to prevent outbreaks. Another

important consideration is the degree of heterogeneity in transmission between different

infected individuals. For a range of pathogens, including SARS-CoV-2, the majority of

transmissions are generated by a relatively small proportion of infectious hosts [63–65].

We therefore also conducted a supplementary analysis in which we considered the

dependence of outbreak risk estimates following the completion of vaccination

programmes in the Isle of Man and Israel on the assumed individual-level variation in

SARS-CoV-2 transmission. While a higher degree of heterogeneity (i.e. a higher

probability of "superspreading" events) acts to lower the outbreak risk, in each scenario

explored outbreaks were still possible in low prevalence settings following vaccination

programmes when NPIs are removed (Fig S4).

To summarise, our analyses have demonstrated the general principle that, even

following vaccination programmes in low prevalence settings, the risk of outbreaks

remains when NPIs are removed. Our intention is not to argue that travel restrictions

and other NPIs should not be relaxed once vaccination programmes are sufficiently

advanced, but rather that measures should be taken to ensure that any clusters of

cases are suppressed quickly if they arise. A local outbreak requires two steps: first, the

virus must be imported from elsewhere; second, local transmission must occur. The first

step emphasises the need for a global approach to minimising transmission, since

higher case numbers at a potential source location translate into a higher importation

risk. The second step emphasises the need to ensure that, while vaccination acts to

reduce transmission substantially, continued surveillance of inbound passengers for

infection, combined with isolation and/or testing of contacts of detected infected

individuals, is important when travel restrictions and other NPIs are relaxed. These

measures are necessary, since only once the global prevalence of SARS-CoV-2

infections is reduced substantially can the risk of outbreaks in low prevalence settings

be eliminated.

COMPETING INTERESTS

We have no competing interests.

DATA ACCESSIBILITY

All data required to reproduce the results presented here are available at

https://github.com/robin-thompson/Outbreaks_Low_Prevalence_Settings/. Data are also

shown in Figs 2a and 2d. No restrictions exist on data availability.

CODE AVAILABILITY STATEMENT

All code required to reproduce the results presented here are available at
https://github.com/robin-thompson/Outbreaks_Low_Prevalence_Settings/, along with
relevant documentation.

AUTHORS' CONTRIBUTIONS

Conceptualization: RS-P, RNT, LD; Methodology: RS-P, RNT; Investigation: RS-P;
Supervision: RNT, HMB; Writing – original draft: RNT, RS-P; Writing – review and editing:
All authors.

FUNDING

RS-P is supported by the EPSRC through the Centre for Doctoral Training in Industrially
Focussed Mathematical Modelling at the University of Oxford (grant EP/L015803/1), in
collaboration with Biosensors Beyond Borders Ltd. LD was supported by the MRC
through the COVID-19 Rapid Response Rolling Call (grant MR/V009761/1) and by UKRI
through the JUNIPER modelling consortium (grant MR/V038613/1). The funders had no
role in study design, data collection and analysis, preparation of the manuscript or the
decision to publish.

ACKNOWLEDGEMENTS

We thank members of the Wolfson Centre for Mathematical Biology (University of Oxford)
and the Zeeman Institute for Systems Biology and Infectious Disease Epidemiology
Research (University of Warwick) for helpful discussions about this work. We also thank

the two anonymous reviewers, and Ed Hill, for helpful feedback that enabled us to improve

this manuscript.

520   **REFERENCES**

1.   Liu Y, Morgenstern C, Kelly J, Lowe R, Jit M. The impact of non-pharmaceutical

interventions on SARS-CoV-2 transmission across 130 countries and territories.

BMC Med. 2021;19: 40.

2.   Leung K, Wu JT, Liu D, Leung GM. First-wave COVID-19 transmissibility and

severity in China outside Hubei after control measures, and second-wave

scenario planning: a modelling impact assessment. Lancet. 2020;395: 1382–

1393.

3.   Cowling BJ, Ali ST, Ng TWY, Tsang TK, Li JCM, Fong MW, et al. Impact

assessment of non-pharmaceutical interventions against coronavirus disease

2019 and influenza in Hong Kong: an observational study. Lancet Public Heal.

2020;4: 397–404.

4.   Chinazzi M, Davis JT, Ajelli M, Gioannini C, Litvinova M, Merler S, et al. The

effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-

19) outbreak. Science (80-). 2020;368: 395–400.

5.   Daon Y, Thompson RN, Obolski U. Estimating COVID-19 outbreak risk through

air travel. J Travel Med. 2020;27: taaa093.

6.   Prem K, Liu Y, Russell TW, Kucharski AJ, Eggo RM, Davies N, et al. The effect of

control strategies to reduce social mixing on outcomes of the COVID-19 epidemic

540  in Wuhan, China: a modelling study. Lancet Public Heal. 2020;5: e261–e270.

541 7. Harris RJ, Hall JA, Zaidi A, Andrews NJ, Dunbar JK, Dabrera G. Impact of

542  vaccination on household transmission of SARS-COV-2 in England. medRxiv.

543  2021.

544 8. Rossman H, Shilo S, Meir T, Gorfine M, Shalit U, Segal E. COVID-19 dynamics

545  after a national immunization program in Israel. Nat Med. 2021.

546 9. Shah AS, Gribben C, Bishop J, Hanlon P, Caldwell D, Wood R, et al. Effect of

547  vaccination on transmission of COVID-19: an observational study in healthcare

548  workers and their households. medRxiv. 2021.

549 10. Richterman A, Meyerowitz EA, Cevik M. Indirect protection by reducing

550  transmission: Ending the pandemic with SARS-CoV-2 vaccination. Open Forum

551  Infect Dis. 2021; ofab259.

552 11. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety

553  and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383.

554 12. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al.

555  Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-

556  CoV-2: an interim analysis of four randomised controlled trials in Brazil, South

557  Africa, and the UK. Lancet. 2021;397.

558 13. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and

559  Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384.

560 14. Baker MG, Wilson N, Blakely T. Elimination could be the optimal response

561  strategy for covid-19 and other emerging pandemic diseases. BMJ. 2020;371.

562 15. Huang QS, Wood T, Jelley L, Jennings T, Jefferies S, Daniells K, et al. Impact of

the COVID-19 nonpharmaceutical interventions on influenza and other respiratory

viral infections in New Zealand. Nat Commun. 2021;12.

16.   Baker MG, Wilson N, Anglemyer A. Successful elimination of Covid-19

transmission in New Zealand. N Engl J Med. 2020;383.

17.   Russell TW, Wu JT, Clifford S, Edmunds WJ, Kucharski AJ, Jit M, et al. Effect of

internationally imported cases on internal spread of COVID-19: a mathematical

modelling study. Lancet Public Heal. 2021;6: e12-20.

18.   Hellewell J, Abbott S, Gimma A, Bosse NI, Jarvis CI, Russell TW, et al. Feasibility

of controlling COVID-19 outbreaks by isolation of cases and contacts. Lancet

Glob Heal. 2020;8: e488–e496.

19.   Thompson RN. Novel coronavirus outbreak in Wuhan, China, 2020: Intense

surveillance is vital for preventing sustained transmission in new locations. J Clin

Med. 2020;9: 498.

20.   Keeling MJ, Moore S, Dyson L, Tildesley MJ, Hill EM. Road map scenarios and

sensitivity. 2021. Available:

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/atta

chment_data/file/975911/S1184_SPI-

M_University_of_Warwick_Road_Map_Scenarios_and_Sensitivity.pdf

21.   Moore S, Hill EM, Tildesley MJ, Dyson L, Keeling MJ. Vaccination and non-

pharmaceutical interventions for COVID-19: a mathematical modelling study.

Lancet Infect Dis. 2021;S1473-3099: 00143–2.

22.   Razai MS, Osama T, McKechnie DGJ, Majeed A. Covid-19 vaccine hesitancy

among ethnic minority groups. BMJ. 2021.

23. Davies N, Abbott S, Barnard R, Jarvis C, Kucharski A, Munday J, et al. Estimated
transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science
(80-). 2021.

24. Althaus CL, Low N, Musa EO, Shuaib F, Gsteiger. Ebola virus disease outbreak
in Nigeria: Transmission dynamics and rapid control. Epidemics. 2015;11: 80–84.

25. Thompson RN, Gilligan CA, Cunniffe NJ. Detecting presymptomatic infection is
necessary to forecast major epidemics in the earliest stages of infectious disease
outbreaks. PLoS Comput Biol. 2016;12: e1004836.

26. Merler S, Ajelli M, Fumanelli L, Parlamento S, y Piontti AP, Dean NE, et al.
Containing Ebola at the source with ring vaccination. PLoS Negl Trop Dis.
2016;10: e0005093.

27. Fraser C. Estimating individual and household reproduction numbers in an
emerging epidemic. PLoS One. 2007;2: e758.

28. White LF, Moser CB, Thompson RN, Pagano M. Statistical estimation of the
reproductive number from case notification data. Am J Epidemiol. 2020; kwaa211.

29. Thompson RN, Stockwin JE, Gaalen RD Van, Polonsky JA, Kamvar ZN, Demarsh
PA, et al. Improved inference of time-varying reproduction numbers during
infectious disease outbreaks. Epidemics. 2019;19: 100356.

30. Isle of Man Government. COVID-19 Vaccination Programme. 2021 [cited 15 Apr
2021]. Available: https://covid19.gov.im/about-coronavirus/open-data-downloads/

31. Our World in Data. Coronavirus (COVID-19) vaccinations. 2021 [cited 23 Apr
2021]. Available: https://ourworldindata.org/covid-vaccinations

32. Bromiley J, Hart WS, Iwami S, Thompson RN. Assessing the threat from

emerging infectious diseases in seasonally varying environments. preprint. 2021.

33. Keeling MJ, Rohani P. Modeling infectious diseases in humans and animals. Princeton University Press; 2008.

34. Thompson RN, Gilligan CA, Cunniffe NJ. Will an outbreak exceed available resources for control? Estimating the risk from invading pathogens using practical definitions of a severe epidemic. J R Soc Interface. 2020;17: 20200690.

35. Carmona P, Gandon S. Winter is coming: Pathogen emergence in seasonal environments. PLoS Comput Biol. 2020;16: e1007954.

36. Ball FG. The threshold behaviour of epidemic models. J Appl Probab. 1983;20: 227–241.

37. Bacaër N, Ait Dads EH. On the probability of extinction in a periodic environment. J Math Biol. 2014;68: 533–548.

38. Kendall DG. On the generalized "birth-and-death" process. Ann Math Stat. 1948;19: 1–15.

39. Gillespie DT. Exact stochastic simulation of coupled chemical reactions. J Phys Chem. 1977;8: 2340–2361.

40. Billah MA, Miah MM, Khan MN. Reproductive number of coronavirus: A systematic review and meta-analysis based on global level evidence. PLoS One. 2020;15.

41. Kucharski AJ, Klepac P, Conlan AJK, Kissler SM, Tang ML, Fry H, et al. Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different settings: a mathematical modelling study. Lancet Infect Dis. 2020;20.

632 42. Centers for Disease Control and Prevention. Interim public health

633   recommendations for fully vaccinated people. 2021.

634 43. Sallam M. Covid-19 vaccine hesitancy worldwide: A concise systematic review of

635   vaccine acceptance rates. Vaccines. 2021.

636 44. Worldometer. Current world population. 2021 [cited 21 Apr 2021]. Available:

637   https://www.worldometers.info/world-population/

638 45. Isle of Man Government. Frequently asked questions about the vaccine. 2021.

639 46. Wise J. Covid-19: Pfizer BioNTech vaccine reduced cases by 94% in Israel,

640   shows peer reviewed study. BMJ. 2021;372.

641 47. Klein B, MacDonald PDM. The multitype continuous-time Markov branching

642   process in a periodic environment. Adv Appl Probab. 1980;12: 81–93.

643 48. Jagers P, Nerman O. Branching processes in periodically varying environment.

644   Ann Probab. 1985;13: 254–268.

645 49. Nipa KF, Allen LJS. Disease emergence in multi-patch stochastic epidemic

646   models with demographic and seasonal variability. Bull Math Biol. 2020;82: 152.

647 50. Bacaër N, Ed-Darraz A. On linear birth-and-death processes in a random

648   environment. J Math Biol. 2014;69: 73–90.

649 51. Hellewell J, Abbott S, Gimma A, Bosse NI, Jarvis CI, Russell TW, et al. Feasibility

650   of controlling COVID-19 outbreaks by isolation of cases and contacts. Lancet

651   Glob Heal. 2020;8: E488-496.

652 52. Lovell-Read FA, Funk S, Obolski U, Donnelly CA, Thompson RN. Interventions

653   targeting non-symptomatic cases can be important to prevent local outbreaks:

654   SARS-CoV-2 as a case study. J R Soc Interface. 2021;18: 20201014.

655   53.   Anderson RM, Vegvari C, Truscott J, Collyer BS. Challenges in creating herd

656   immunity to SARS-CoV-2 infection by mass vaccination. The Lancet. 2020. p.

657   10263.

658   54.   Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the

659   transmission dynamics of SARS-CoV-2 through the postpandemic period.

660   Science (80-). 2020;368: 860–868.

661   55.   Crellen T, Pi L, Davis EL, Pollington TM, Lucas TCD, Ayabina D, et al. Dynamics

662   of SARS-CoV-2 with waning immunity in the UK population. Philos Trans R Soc B

663   Biol Sci. 2021;376: 20200274.

664   56.   Pritchard E, Matthews PC, Stoesser N, Eyre DW, Gethings O, Vihta K-D, et al.

665   Impact of vaccination on SARS-CoV-2 cases in the community: a population-

666   based study using the UK's COVID-19 Infection Survey. medRxiv.

667   57.   Gog JR, Hill EM, Danon L, Thompson RN. Vaccine escape in heterogeneous

668   populations: insights for SARS-CoV-2 from a simple model. medRxiv. 2021.

669   58.   Zuo J, Dowell AC, Pearce H, Verma K, Long HM, Begum J, et al. Robust SARS-

670   CoV-2-specific T cell immunity is maintained at 6 months following primary

671   infection. Nat Immunol. 2021;22: 620–626.

672   59.   Tea F, Stella AO, Aggarwal A, Darley DR, Pilli D, Vitale D, et al. SARS-CoV-2

673   neutralizing antibodies: longevity, breadth, and evasion by emerging viral variants.

674   PLoS Med. 2021;18: e1003656.

675   60.   Bubar KM, Reinholt K, Kissler SM, Lipsitch M, Cobey S, Grad YH, et al. Model-

676   informed COVID-19 vaccine prioritization strategies by age and serostatus.

677   Science (80-). 2021;371.

61. Britton T, Ball F, Trapman P. A mathematical model reveals the influence of

population heterogeneity on herd immunity to SARS-CoV-2. Science (80-). 2020.

62. Davies NG, Klepac P, Liu Y, Prem K, Jit M, CMMID COVID-19 Working Group, et

al. Age-dependent effects in the transmission and control of COVID-19 epidemics.

Nat Med. 2020.

63. Thompson RN, Hollingsworth TD, Isham V, Arribas-Bel D, Ashby B, Britton T, et

al. Key questions for modelling COVID-19 exit strategies. Proc R Soc B Biol Sci.

2020;287: 20201405.

64. Endo A, CMMID COVID-19 working group, Abbott S, Kucharski AJ, Funk S.

Estimating the overdispersion in COVID-19 transmission using outbreak sizes

outside China. Wellcome Open Res. 2020;5: 67.

65. Lloyd-Smith JO, Schreiber SJ, Kopp PE, Getz WM. Superspreading and the effect

of individual variation on disease emergence. Nature. 2005;438: 355–359.

691